Antileukemic effects of rapid cyclosporin withdrawal in patients with relapsed chronic myeloid leukemia after allogeneic bone marrow transplantation

Leukemia and Lymphoma

Volumn 31, Issue 5-6, 1998, Pages 545-550

  Brandenburg, Ulrike ^a,b   Gottlieb, David ^a   Bradstock, Kenneth ^a  

^a WESTMEAD HOSPITAL   (Australia)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Bone marrow transplantation; Chronic myeloid leukemia; Cyclosporin; Graft versus host; Graft versus leukemia

Indexed keywords

CYCLOSPORIN;

ADOLESCENT; ADULT; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; CANCER RECURRENCE; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG WITHDRAWAL; FEMALE; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; HUMAN; LEUKEMIA REMISSION; MALE; ORAL DRUG ADMINISTRATION; PHILADELPHIA 1 CHROMOSOME; PRIORITY JOURNAL;

EID: 0032449718     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.3109/10428199809057613     Document Type: Article

References (13)

1. Goldman JM, Apperly JF, Jones L, Marous R, Goolden AM, Batchelor R, Hale G, Waldman H, Reid CD, Hows J, Gordon-Smith E, Catovsky D, Galton DAG (1986). Bone marrow transplantation for patients with chronic myeloid leukemia. N Engl J Med 314: 202-207.
2. Clift RA, Appelbaum FR, Thomas ED (1993). Treatment of chronic myeloid leukemia by marrow transplantation. Blood 82: 1954-1956.
3. Enright H, Davies SM, De For T, Shu X, Weisdorf E, Miller W, Ramsay NKC, Arthur D, Verfaillie C, Miller J, Kersey J, McGlave P. (1996). Relapse after non-T-cell-depleted allogeneic bone marrow transplantation, for chronic myeloid leukemia; early transplantation, use of an unrelated donor, and chronic graft-versus-host disease are protective. Blood 88: 714-720.
4. Kantarajan HM, O'Brien S, Anderlini P, Talpaz M (1996). Treatment of chronic myelogenous leukemia: current status and investigational options. Blood 87: 3069-3081.
5. Horowitz MM, Gale RP, Sondel PM, Goldman JM, Kersey J, Kolb HJ, Rimm AA, Ringden O, Rozman C, Speck B, Truitt RL, Zwann FE, Bortin MM (1990). Graft-versus-leukemia reactions after bone marrow transplantation. Blood 75: 555-562.
6. Goldman JM, Gale RP, Horowitz MM, Biggs JC, Champlin RE, Gluckman E, Hoffman RG, Jacobsen SJ, Marmont AM, McGlave PB, Messner HA, Rimm AA, Rozman C, Speck B, Tura S, Weiner RS, Bortin MM (1988). Bone marrow transplantation for chronic myelogenous leukemia in chronic phase: increased risk of relapse associated with T-cell depletion. Ann Intern Med 108: 806-815.
7. Kolb HG, Mittermueller J, Clemm C, Holler E, Ledderose G, Brehm G, Heim M, Wilmanns W (1990). Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood 76: 2462-2465.
8. Kolb HJ, Schattenberg A, Goldman JM, Hertenstein B, Jacobsen N, Arcese W, Ljungman P, Ferrant A, Verdonck L, Niederwieser D, van Rhee F, Mittermueller J, de Witte T, Holler E, Ansari H. (1995). Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood 86: 2041-2050.
9. Frassoni F, Sessarego M, Bacigalupo A, Strada P, Repetto M, Miceli S, Occhini D, Defferrari R, Marmont A (1988). Competition between recipient and donor cells after bone marrow transplantation for chronic myeloid leukaemia. Brit Jnl Haem 69: 471-475.
10. Alkam M, Bradstock KF, Hughes WG, Watson N, Bowyer I. (1990). Spontaneous complete remission of chronic myeloid leukaemia following haematological relapse after allogeneic bone marrow transplantation. Aust NZ J Med 20: 710-712.
11. Bocchia M, Korontsuit T, Xu Q, Mackinnon S, Yang SY, Sette A, Scheinberg DA (1996). Specific human cellular immunity to bcr-abl ongene-derived peptides. Blood 87: 3587-3592.
12. Vogelsang GB, Hess AD (1994). Graft-versus-host disease: new directions for,a persistent problem. Blood 84: 2061-2067.
13. Jones RJ, Vogelsang GB, Hess AD, Farmer ER, Mann RB, Geller RB, Piantadosi S, Santos GW (1989). Induction of graft-versus-host disease after autologous bone marrow transplantation. Lancet I: 754-756.